Cover Image
市場調查報告書

製藥·生化科技·診斷的共同推廣及聯合行銷的合作規章·協定

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 239653
出版日期 內容資訊 英文 580 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
製藥·生化科技·診斷的共同推廣及聯合行銷的合作規章·協定 Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2016
出版日期: 2016年09月01日 內容資訊: 英文 580 Pages
簡介

本報告提供全球主要醫療保健企業的共同推廣及聯合行銷合作的相關調查,共同推廣·聯合行銷交易趨勢·協定結構·契約文件,不同契約金額的主要交易及的最活躍的仲介業者等分析,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 共同推廣·聯合行銷交易的功能趨勢

  • 簡介
  • 共同推廣和聯合行銷交易的差異
  • 共同推廣交易趨勢
  • 聯合行銷交易趨勢
  • 專用交易和多組件交易
  • 交易共同推廣可供選擇的理由
  • 共同推廣權的普及
  • 作為談判籌碼的共同推廣權
  • 共同促銷工作的合作夥伴的合作
  • 作為多組件交易一部分的共同推廣的未來

第3章 共同推廣交易結構概要

  • 簡介
  • 專用vs.多組件的共同推廣交易
  • 專用共同推廣協定結構
  • 作為廣泛聯盟協定一部分的共同推廣權
  • 編入的共同推廣權使第三方的參與成為可能

第4章 聯合行銷交易結構概要

  • 簡介
  • 聯合行銷協定結構
  • 作為廣泛的聯盟協定一部分的聯合行銷權

第5章 主要合作推廣交易

  • 簡介
  • 主要合作推廣交易:各交易金額
  • 最活躍的合作推廣仲介企業
  • 大型製藥企業的合作推廣交易活動
  • 大生物工學企業的合作推廣交易活動

第6章 主要聯合行銷交易

  • 簡介
  • 主要聯合行銷交易:各交易金額
  • 最活躍的聯合行銷仲介企業
  • 大型製藥企業的聯合行銷交易活動

第7章 大型製藥企業的共同推廣·聯合行銷交易

  • 簡介
  • 共同推廣·聯合行銷交易的利用法
  • 企業的共同推廣·聯合行銷協定清單

第8章 共同推廣協定名錄

  • 簡介
  • 企業:A - Z
  • 治療各領域

第9章 聯合行銷協定名錄

  • 簡介
  • 企業:A - Z
  • 治療各領域

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2050

The ‘Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016’ report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies

The ‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2010 to 2016.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 50 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2010 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2010.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits

‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report provides the reader with the following key benefits:

  • In-depth understanding of co-promotion and co-marketing deal trends since 2010
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 700 actual co-promotion and co-marketing deals entered into by the world's biopharma companies
  • Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ includes:

  • Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2010
  • Analysis of co-promotion and co-marketing deal structure
  • Case studies of real-life co-promotion and co-marketing deals
  • Access to over 700 co-promotion and co-marketing deal records
  • Detailed access to actual co-promotion contract documents
  • The leading co-promotion and co-marketing deals by value since 2010
  • Most active co-promotion and co-marketing dealmakers since 2010
  • The leading co-promotion and co-marketing partnering resources

In ‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology area

Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

The ‘Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2016’ report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise co-promotion and co-marketing rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016’ provides the reader with the following key benefits:

  • In-depth understanding of co-promotion and co-marketing deal trends since 2010
  • Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
  • Comprehensive access to over 800 co-promotion and co-marketing deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual co-promotion and co-marketing contracts entered into by the leading fifty big pharma and big biotech companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Identify leading co-promotion and co-marketing deals by value since 2010
  • Identify the most active co-promotion and co-marketing dealmakers since 2010
  • Full listing of co-promotion and co-marketing deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking

  • 2.1. Introduction
  • 2.2. Difference between co-promotion and co-marketing deals
  • 2.3. Trends in co-promotion deals since 2010
    • 2.3.1. Co-promotion and co-marketing dealmaking by year, 2010 to 2016
    • 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2010 to 2016
    • 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2010 to 2016
    • 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2010 to 2016
    • 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2010 to 2016
    • 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2010 to 2016
  • 2.4. When co-marketing can be useful
  • 2.5. When co-marketing is the only option
  • 2.6. Pure deals and multi-component deals
    • 2.6.1. Attributes of pure co-promotion deals
    • 2.6.2. Attributes of co-promotion in multi-component deals
  • 2.7. Reasons for including co-promotion options in a deal
  • 2.8. Uptake of co-promotion rights
  • 2.9. Co-promotion rights as bargaining chips
  • 2.10. Aligning partners to make the co-promote work
  • 2.11. The future of co-promotion as part of multicomponent deals

Chapter 3 - Overview of co-promotion deal structure

  • 3.1. Introduction
  • 3.2. Pure versus multi-component co-promotion deals
  • 3.3. Pure co-promotion agreement structure
    • 3.3.1. Example co-promotion agreements
    • 3.3.1.a. Case study 1: Allergan - MAP Pharmaceuticals
    • 3.3.1.b. Case study 2: Genzyme - Veracyte
  • 3.4. Co-promotion rights as part of a wider alliance agreement
    • 3.4.1. Example co-promotion option clauses
    • 3.4.1.a. Case study 3: Takeda Pharmaceutical- Orexigen Therapeutics
    • 3.4.1.b. Case study 4: Celgene - Acceleron Pharma
    • 3.4.2. Example co-promotion right clauses
    • 3.4.2.a. Case study 5: Takeda - Orexigen
    • 3.4.2.b. Case study 6: Abbvie - Receptos
  • 3.5. Embedded co-promotion rights enabling third party engagement
    • 3.5.1. Example co-promotion clauses enabling third party engagement
    • 3.5.1.a. Case study 7: Astellas - Ambit Biosciences

Chapter 4 - Overview of co-marketing deal structure

  • 4.1. Introduction
  • 4.2. Co-marketing agreement structure
    • 4.2.1. Example co-marketing agreements
    • 4.2.1.a. Case study 8: AstraZeneca -Ironwood Pharmaceuticals
  • 4.3. Co-marketing rights as part of a wider alliance agreement
    • 4.3.1. Example co-marketing right clauses
    • 4.3.1.a. Case study 9: Lundbeck - Myriad Genetics

Chapter 5 - Leading co-promotion and co-marketing deals

  • 5.1. Introduction
  • 5.2. Top co-promotion and co-marketing deals by value

Chapter 6 - Top 50 most active co-promotion and co-marketing dealmakers

  • 6.1. Introduction
  • 6.2. Top 50 most active co-promotion and co-marketing dealmakers

Chapter 7 - Co-promotion and co-marketing agreement contracts directory 2010- 2016

  • 7.1. Introduction
  • 7.2. Co-promotion and co-marketing deals with contracts 2010 to 2016

Appendices

  • Appendix 1 - Co-promotion and co-marketing deals by company A-Z
  • Appendix 2 - Co-promotion and co-marketing deals by stage of development
  • Appendix 3 - Co-promotion and co-marketing deals by deal type
  • Appendix 4 - Co-promotion and co-marketing deals by therapy area
  • Appendix 5 - Co-promotion and co-marketing deals by technology type
  • Appendix 6 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of co-promotion and co-marketing
  • Figure 2: Trends in co-promotion and co-marketing deal announcements, 2010 to 2016
  • Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2010 to 2016
  • Figure 4: Co-promotion and co-marketing deals by industry sector, 2010 to 2016
  • Figure 5: Co-promotion and co-marketing deals by therapy area, 2010 to 2016
  • Figure 6: Co-promotion and co-marketing deals by technology type, 2010 to 2016
  • Figure 7: Top 50 most active co-promotion and co-marketing dealmakers, 2010 to 2016
  • Figure 8: Situations where co-marketing can prove useful
  • Figure 9: Key components of a pure co-promotion deal
  • Figure 10: Key components of a multi-component co-promotion deal
  • Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
  • Figure 12: Issues in implementing co-promotion agreements
  • Figure 13: Co-promotion agreements - what should a contract include?
  • Figure 14: Components of the co-promotion deal structure
  • Figure 15: Components of the co-marketing deal structure
  • Figure 16: Top co-promotion and co-marketing deals by value since 2010
  • Figure 17: Most active co-promotion and co-marketing dealmakers 2010 to 2016
Back to Top